Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  AstraZeneca plc    AZN   GB0009895292

News SummaryMost relevantAll newsSector news 

UK Health Watchdog Backs Lung Cancer Drug From Roche

05/09/2012 | 07:16pm US/Eastern

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
React to this article
Latest news on ASTRAZENECA PLC
05:02p ASTRAZENECA : US FDA approves expanded indication for BRILINTA to include long-t..
06:42a DAIICHI SANKYO : Enters License Agreement with AstraZeneca for Development and C..
03:49a ASTRAZENECA : City awaits economic benefits expected from AstraZeneca, Flying Do..
12:37a ASTRAZENECA : and Heptares Therapeutics enter agreement to develop novel immuno-..
09/02 Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical ..
09/02 AstraZeneca and Valeant to partner on brodalumab
09/02 ASTRAZENECA : Positive Phase III results demonstrate efficacy of antibiotic medi..
09/02 ASTRAZENECA : Signs Flu Vaccine Licensing Deal With Daiichi Sankyo
09/02 ASTRAZENECA : *hsbc raises astrazeneca to 'buy' ('hold') - price target 4600 pen..
09/02 ASTRAZENECA : enters license agreement with Daiichi Sankyo for development and c..
Duration : Period :
AstraZeneca plc Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Income Statement Evolution
More Financials